Clinical trials: Neuropsychiatric Symptom
Alzheimer's Disease
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil.
- Trial name
- NCT01712074
- Testing
- PF-05212377 (SAM-760)
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 186 people
- Sponsor
- Pfizer
Smoking Cessation
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.
- Trial name
- NCT00749944
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Parkinson's Disease
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
This is a pilot study to explore the effects of pimavanserin and low-dose quetiapine in subjects with Parkinson's disease with neuropsychiatric symptoms.
- Trial name
- NCT04164758
- Testing
- Pimavanserin, Quetiapine
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer's Disease
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's disease.
- Trial name
- NCT00843518
- Testing
- LY451395
- Where
- 17 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
- Trial name
- EpiCom (NCT05864846)
- Testing
- Cannabidiol Oral Solution [Epidiolex]
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 79 people
- Sponsor
- Jazz Pharmaceuticals
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
Depression, Anxiety
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of…
- Trial name
- NCT02411123
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- AltheaDx
Phenylketonuria
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
- Trial name
- NCT01114737
- Testing
- Sapropterin dihydrochloride
- Where
- 36 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- BioMarin Pharmaceutical
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
- Trial name
- NCT03575052
- Testing
- Pimavanserin
- Where
- 104 sites in United States, Bulgaria and 10 more
- Volunteers
- 784 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Perceptual Disorders, Confusion
Ketamine Challenge Study With JNJ-40411813
The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine.
- Conditions
- Perceptual Disorders, Confusion, Schizophrenia
- Trial name
- NCT01101659
- Testing
- JNJ-40411813, normal saline, ketamine
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression, Anxiety
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or…
- Trial name
- NCT02878928
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- 17 sites in United States
- Volunteers
- 579 people
- Sponsor
- AltheaDx
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin…
- Trial name
- NCT03623321
- Testing
- Pimavanserin
- Where
- 88 sites in United States, Bulgaria and 10 more
- Volunteers
- 595 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Agitation, Alzheimer's Disease
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
- Trial name
- NCT01584440
- Testing
- AVP-923-20, AVP-923-30
- Where
- 44 sites in United States
- Volunteers
- 220 people
- Sponsor
- Avanir Pharmaceuticals